Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 9/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | IL1B | P01584 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5115577 | 0.90 | P2RX7 (0.69) | P2RX7KDM4EALDH1A1GAACHRM1 | |
| SCHEMBL27698865 | 0.90 | P2RX7 (0.53) | P2RX7CHRM1KMT2AMEN1CHRM4 | |
| SCHEMBL5115009 | 0.85 | P2RX7 (0.63) | P2RX7ALDH1A1CHRM1KMT2AMEN1 | |
| SCHEMBL5119633 | 0.82 | P2RX7 (0.84) | P2RX7CHRM1KMT2AMEN1CHRM4 | |
| SCHEMBL5110613 | 0.81 | P2RX7 (0.44) | P2RX7KMT2AMEN1 | |
| SCHEMBL5115561 | 0.80 | P2RX7 (0.45) | P2RX7CHRM1KMT2AMEN1CHRM4 | |
| SCHEMBL5111394 | 0.80 | P2RX7 (0.73) | P2RX7 | |
| SCHEMBL4880198 | 0.79 | P2RX7 (0.57) | P2RX7KMT2A | |
| SCHEMBL4875200 | 0.77 | P2RX7 (0.66) | P2RX7 | |
| SCHEMBL4876545 | 0.76 | ALDH1A1 (0.51) | KDM4EALDH1A1GAAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080146612-A1 | Novel Biaromatic Compounds, Inhibitors of the P2X7-Receptor | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | claimed |
| CN-101151239-A | Novel biaromatic compounds, inhibitors of the P2X7-receptor | ASTRAZENECA AB (SE) | 2008-03-26 | — | — | CN | claimed |
| US-20080146612-A1 | Novel Biaromatic Compounds, Inhibitors of the P2X7-Receptor | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | disclosed |
| US-20080146612-A1 | Novel Biaromatic Compounds, Inhibitors of the P2X7-Receptor | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | disclosed |
| US-20080146612-A1 | Novel Biaromatic Compounds, Inhibitors of the P2X7-Receptor | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | disclosed |
| CN-101151239-A | Novel biaromatic compounds, inhibitors of the P2X7-receptor | ASTRAZENECA AB (SE) | 2008-03-26 | — | — | CN | disclosed |
| EP-1844003-A1 | NOVEL BIAROMATIC COMPOUNDS, INHIBITORS OF THE P2X7-RECEPTOR | AstraZeneca AB (SE) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006080884-A1 | NOVEL BIAROMATIC COMPOUNDS, INHIBITORS OF THE P2X7-RECEPTOR | ASTRAZENECA AB (SE) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146612-A1 | Novel Biaromatic Compounds, Inhibitors of the P2X7-Receptor | P2RX2, P2RX1, ADORA1 | P2RX7 4/4885KDM4E 3654/4885ALDH1A1 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.